P-014 Teclistamab in Relapsed and Refractory Multiple Myeloma: Patients Characteristics from Post Marketing Acces (acces Precoce) in France

S40pts, including viral, bacterial, and fungal.Five (18%) infections were deemed severe and required hospitalization.Prior to TEC, 14 (50%) pts had hypogammaglobulinemia (IgG< 400).After TEC, 8 pts (29%) developed new hypogammaglobulinemia.Eleven (39%) pts had treatment delays, mainly due to CRS and infections.Four pts died; 1 due to infection, and 3 due to progression of disease.Conclusions: Pts treated with SOC TEC had a favorable ORR (52%) despite no pts meeting MajesTEC-1 trial eligibility criteria.No new safety signals were identified.Results will be updated with continued follow up.